ArticleThe Journal of clinical endocrinology and metabolism2008
Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
Article in The Journal of clinical endocrinology and metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07224334 (Alpha to Beta Cell Communication in Health and Disease), which is not on this map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Alpha to Beta Cell Communication in Health and Disease
Open the trial in the graphWho cites it
51 citing papers in PubMed, 106 citations in OpenAlex.
- Trial
- Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women.Journal of the American Heart Association · 2018Trial
- GIP(3-30)NHDiabetologia · 2018Trial
- Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1.The Journal of clinical endocrinology and metabolism · 2016Trial
- Trial
- β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.The Journal of clinical endocrinology and metabolism · 2015Trial
- Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans.Appetite · 2014Trial
- High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans.Diabetes · 2024 · on this mapArticle
- Assessment of the incretin effect in healthy subjects: concordance between clamp and OGTT methods.American journal of physiology. Endocrinology and metabolism · 2023Article
- Noncanonical Regulation of cAMP-Dependent Insulin Secretion and Its Implications in Type 2 Diabetes.Comprehensive Physiology · 2023Article
- Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice.Biomedicines · 2023Article
- Review
- The Role of Incretins on Insulin Function and Glucose Homeostasis.Endocrinology · 2021Review
- GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.The Journal of clinical endocrinology and metabolism · 2020Review
- Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.Gene expression · 2019Review
- Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes.Scientific reports · 2019Article
- Postprandial Glucose Control in Type 1 Diabetes: Importance of the Gastric Emptying Rate.Nutrients · 2019Review
- Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database.Journal of pharmaceutical health care and sciences · 2018Article
- Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors.Scientific reports · 2017Article
- Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats.Endocrinology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundExogenous administration of glucagon-like peptide (GLP)-1 improves glucose tolerance by stimulation of insulin secretion, inhibition of glucagon secretion, and delay of gastric emptying. It is not known which of these effects is involved in the action of endogenous GLP-1 to control blood glucose. To determine the role of endogenous GLP-1 on islet cell function and gastric emptying independent of variable glycemia, we clamped blood glucose before and during glucose ingestion with and without GLP-1 receptor blockade with exendin-[9-39] (Ex-9).
methodsThere were 10 healthy subjects that participated in two experiments each, one a control and one with infusion of 750 pm/kg . min Ex-9. Subjects consumed 75 g oral glucose solution mixed with d-xylose and (13)C-glucose while their blood glucose levels were held fixed at approximately 8.9 mmol/liter.
resultsPlasma insulin levels during hyperglycemia alone were similar in the two studies (control, 282.5 +/- 42 vs. Ex-9, 263.8 +/- 59 pmol/liter) but were reduced by approximately 30% by Ex-9 after glucose ingestion (control, 1154 +/- 203 vs. Ex-9, 835 +/- 120 pmol/liter; P < 0.05). Blocking the action of endogenous GLP-1 caused an approximate 80% increase in postprandial glucagon concentrations. The appearance of ingested d-xylose in the blood was not affected by Ex-9, suggesting that postprandial secretion of GLP-1 has only minimal effects on gastric emptying of oral glucose.
conclusionsThese findings indicate that GLP-1 is an incretin in healthy humans at modestly supraphysiological blood glucose levels. The primary effect of GLP-1 to regulate oral glucose tolerance is mediated by effects on islet hormones and not on gastric emptying.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.